Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2022-11-14 00:00:00 ET · period of report 2022-11-11 · accession 0001209191-22-056573 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-14 | 2022-11-11 | CBIO | Magnani John L. | CSO, SVP of Research | P - Purchase | $1.17 | +45.0K | 366.1K | +14% | +$52.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-11 | P | A | 45,045 | $1.17 | 366,078 | D | — | — | (F1) The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.10 to $1.20 per share, with a weighted average purchase price of $1.17 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |